

Note: This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original,
the original shall prevail.



March 19, 2026

Fuji Pharma Co., Ltd.

Notice Regarding Revision of Interim Dividend Forecasts for the Fiscal Year Ending September 2026 (62nd Fiscal Year)

Fuji Pharma Co., Ltd. hereby announces that, it has decided, at a meeting of the Board of Directors held on March 19, 2026, to revise its interim dividend forecasts as described below.

1. Reason for revision to dividend forecasts

Our company aims for stable and continuous shareholder returns, and our basic policy is to pay dividends with a target dividend payout ratio of 30% based on operating profit, in addition to adopting a progressive dividend policy.

Sales of our main products have been generally progressing smoothly, and after careful consideration of our financial soundness, we have decided to revise our interim dividend forecast.

2. Details of revision

(Yen)

	Annual dividends		
	Second quarter-end	Fiscal-year end	Total
Previous forecasts (Announced November 11, 2025)	21.00	26.00	47.00
Revised forecasts	23.00	26.00	49.00
Actual results for the current fiscal year	—	—	—
Actual results for the previous fiscal year(Fiscal year ended 9 30, 2026)	20.00	25.50	45.50

The forward-looking statements, including dividend forecasts, contained in this document are based on information available as of the date of publication of this document, and actual dividends may differ from the forecast due to various factors in the future.

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

fsk_ir@fujipharma.jp